Loomis, Sayles & Company
CRSP icon

Loomis, Sayles & Company’s CRISPR Therapeutics CRSP Stock Holding History

Loomis, Sayles & Company’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.1M Buy
968,135
+68,804
+8% +$3.63M 0.06% 108
2025
Q4 		$47.2M Sell
899,331
-10,383
-1% -$622K 0.06% 110
2025
Q3 		$59M Buy
909,714
+52,827
+6% +$3.03M 0.07% 97
2025
Q2 		$41.7M Sell
856,887
-52,905
-6% -$2.05M 0.05% 129
2025
Q1 		$31M Sell
909,792
-1,173
-0.1% -$49.7K 0.04% 165
2024
Q4 		$35.9M Sell
910,965
-34,302
-4% -$1.62M 0.05% 162
2024
Q3 		$44.4M Sell
945,267
-60,946
-6% -$3.09M 0.06% 148
2024
Q2 		$54.3M Sell
1,006,213
-19,030
-2% -$1.1M 0.07% 106
2024
Q1 		$69.9M Sell
1,025,243
-42,108
-4% -$3.01M 0.1% 88
2023
Q4 		$66.8M Sell
1,067,351
-29,003
-3% -$1.6M 0.1% 91
2023
Q3 		$49.8M Sell
1,096,354
-51,575
-4% -$2.66M 0.09% 112
2023
Q2 		$64.4M Sell
1,147,929
-8,881
-0.8% -$504K 0.1% 93
2023
Q1 		$52.3M Sell
1,156,810
-31,511
-3% -$1.53M 0.09% 112
2022
Q4 		$48.3M Sell
1,188,321
-56,878
-5% -$3.02M 0.1% 114
2022
Q3 		$81.4M Sell
1,245,199
-151,059
-11% -$10.9M 0.16% 73
2022
Q2 		$84.8M Buy
1,396,258
+105,353
+8% +$6.19M 0.16% 68
2022
Q1 		$81M Sell
1,290,905
-25,218
-2% -$1.58M 0.11% 80
2021
Q4 		$99.7M Buy
1,316,123
+390,209
+42% +$34.1M 0.12% 75
2021
Q3 		$104M Buy
925,914
+17,262
+2% +$2.17M 0.13% 72
2021
Q2 		$147M Buy
+908,652
New +$111M 0.18% 64

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company's CRSP Position: Q1 2026 in Review

Loomis, Sayles & Company increased its CRISPR Therapeutics (CRSP) stake by 7.7% in Q1 2026, buying an estimated $3.63M and bringing the position to 968,135 shares worth $46.1M. The position accounts for 0.06% of the portfolio, ranked #108.

Loomis, Sayles & Company first reported a position in CRSP in Q2 2021 and has held it in 20 quarters since. The position peaked at $147M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Loomis, Sayles & Company held 968,135 shares of CRISPR Therapeutics worth $46.1M as of Q1 2026.
  • Loomis, Sayles & Company bought 68,804 CRISPR Therapeutics shares in Q1 2026, an estimated $3.63M.
  • CRISPR Therapeutics made up 0.06% of Loomis, Sayles & Company's portfolio in Q1 2026, its #108 holding.
  • Loomis, Sayles & Company first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Loomis, Sayles & Company's CRISPR Therapeutics position peaked at $147M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.